4D Molecular Therapeutics Inc (FDMT)
$14.40
$0.29
(2.06%)
As on 01-Sep-2026 15:40EDT
Market cap
$810 Mln
Revenue (TTM)
$92 Mln
P/E Ratio
--
P/B Ratio
2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-3.6
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-2.7
-
Face value
--
-
Shares outstanding
55,244,211
7 Years Aggregate
CFO
$-327.25 Mln
EBITDA
$-396.64 Mln
Net Profit
$-400.46 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
4D Molecular Therapeutics Inc (FDMT)
| 92.0 | 41.5 | 45.3 | 133.8 | -4.0 | -14.0 | -- |
|
BSE Sensex
| -9.1 | -1.5 | 2.9 | -3.6 | 5.9 | 6.0 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
4D Molecular Therapeutics Inc (FDMT)
| 34.6 | -72.2 | -8.8 | 1.2 | -47.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
4D Molecular Therapeutics Inc (FDMT)
|
14.4 | 810.4 | 92.0 | -179.2 | -209.0 | -39.2 | -- | 2.0 |
| 82.7 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 72.0 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 56.6 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 107.7 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 361.2 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 539.4 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 584.5 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 351.0 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 146.2 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout 4D Molecular Therapeutics Inc (FDMT)
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United... States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California. Read more
-
Executive Chairman
Dr. John F. Milligan Ph.D.
-
Executive Chairman
Dr. John F. Milligan Ph.D.
-
Headquarters
EmeryVille, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for 4D Molecular Therapeutics Inc (FDMT)
What is the current share price of 4D Molecular Therapeutics Inc (FDMT) Today?
The share price of 4D Molecular Therapeutics Inc (FDMT) is $14.40 (NASDAQ) as of 01-Sep-2026 15:40 EDT. 4D Molecular Therapeutics Inc (FDMT) has given a return of -4.01% in the last 3 years.
What is the current PB & PE ratio of 4D Molecular Therapeutics Inc (FDMT)?
Since, TTM earnings of 4D Molecular Therapeutics Inc (FDMT) is negative, P/E ratio is not available.
The P/B ratio of 4D Molecular Therapeutics Inc (FDMT) is 2.02 times as on 28-Aug-2026, a 61 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-3.10 |
0.86 |
2024 |
-1.87 |
0.59 |
2023 |
-7.86 |
2.58 |
2022 |
-7.14 |
3.12 |
2021 |
-8.68 |
1.86 |
What is the 52 Week High and Low of 4D Molecular Therapeutics Inc (FDMT)?
The 52-week high and low of 4D Molecular Therapeutics Inc (FDMT) are Rs 16.91 and Rs 5.97 as of 02-Sep-2026.
What is the market cap of 4D Molecular Therapeutics Inc (FDMT)?
4D Molecular Therapeutics Inc (FDMT) has a market capitalisation of $ 810 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in 4D Molecular Therapeutics Inc (FDMT)?
Before investing in 4D Molecular Therapeutics Inc (FDMT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.